Chemotherapy: Target Therapy and Immunotherapy:@0.423628:0.035749:0.914577:0.035749:0.914577:0.019993:0.423628:0.019993:0.015644:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005330:0.007177:0.013143:0.005809:0.012950:0.012508:0.006523:0.005330:0.008197:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.013143:0.011738:0.013181:0.005330:0.004349:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
15:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
27.  Roila F, Warr D, Hesketh  PJ, :@0.084242:0.094740:0.357322:0.094740:0.357322:0.080735:0.084242:0.080735:0.009476:0.009476:0.004738:0.012657:0.000000:0.010382:0.011203:0.003421:0.003421:0.011682:0.007492:0.006205:0.004738:0.007492:0.015568:0.011682:0.005148:0.005148:0.007492:0.012726:0.004738:0.007492:0.011682:0.011118:0.006636:0.008586:0.011118:0.005798:0.010434:0.004738:0.002745:0.010126:0.008244:0.004738:0.004738
et  al. :@0.360033:0.094740:0.409011:0.094740:0.409011:0.080735:0.360033:0.080735:0.011118:0.005798:0.004738:0.002745:0.011682:0.003421:0.004738:0.004738
Erratum :@0.411765:0.094740:0.479892:0.094740:0.479892:0.080735:0.411765:0.080735:0.009168:0.005148:0.005148:0.011682:0.005798:0.010399:0.016044:0.004738
to: 2016  updated MASCC/ESMO consen-:@0.120589:0.108968:0.475145:0.108968:0.475145:0.094963:0.120589:0.094963:0.005798:0.011203:0.004738:0.008450:0.009476:0.009476:0.009476:0.009476:0.004738:0.003724:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.011716:0.008450:0.015719:0.012657:0.008518:0.013906:0.013906:0.007475:0.009168:0.008518:0.015719:0.014864:0.008450:0.011067:0.011203:0.010434:0.006636:0.011118:0.010422:0.005679
sus recommendations: prevention of nau-:@0.120589:0.123491:0.475178:0.123491:0.475178:0.109486:0.120589:0.109486:0.006636:0.010399:0.006636:0.007167:0.005078:0.011118:0.011067:0.011203:0.016044:0.016044:0.011118:0.010434:0.011716:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.007167:0.011665:0.005080:0.011118:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.007167:0.011203:0.005371:0.007167:0.010434:0.011682:0.010399:0.005679
sea and vomiting  following  moderately :@0.120589:0.138014:0.479899:0.138014:0.479899:0.124009:0.120589:0.124009:0.006636:0.011118:0.011682:0.012349:0.011682:0.010434:0.011716:0.012349:0.009476:0.011203:0.016044:0.003421:0.005798:0.003421:0.010434:0.011511:0.004738:0.007601:0.005371:0.011203:0.003421:0.003421:0.011203:0.014214:0.003421:0.010434:0.011511:0.004738:0.007603:0.016044:0.011203:0.011716:0.011118:0.005148:0.011682:0.005798:0.011118:0.003421:0.009168:0.004738
emetogenic chemotherapy. :@0.120589:0.152537:0.363062:0.152537:0.363062:0.138531:0.120589:0.138531:0.011118:0.016044:0.011118:0.005798:0.011203:0.011511:0.011118:0.010434:0.003421:0.011067:0.005287:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
Support Care :@0.363608:0.152537:0.479892:0.152537:0.479892:0.138531:0.363608:0.138531:0.008518:0.010399:0.011665:0.011665:0.011203:0.005148:0.005798:0.005294:0.013906:0.011682:0.005148:0.011118:0.004738
Cancer.:@0.120589:0.167059:0.188682:0.167059:0.188682:0.153054:0.120589:0.153054:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
 2017 Jan;25(1):295-296.:@0.188665:0.167059:0.384202:0.167059:0.384202:0.153054:0.188665:0.153054:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.008244:0.011682:0.010434:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
28.  Roila F,  Molassiotis A,  Herrstedt  J, :@0.084242:0.181582:0.421301:0.181582:0.421301:0.167577:0.084242:0.167577:0.009476:0.009476:0.004738:0.012657:0.000000:0.010382:0.011203:0.003421:0.003421:0.011682:0.010930:0.006207:0.004738:0.004738:0.006178:0.015719:0.011203:0.003421:0.011682:0.006636:0.006636:0.003421:0.011203:0.005798:0.003421:0.006636:0.010930:0.012657:0.004738:0.004738:0.006176:0.011682:0.011118:0.005148:0.005148:0.006636:0.005798:0.011118:0.011716:0.005798:0.004738:0.006171:0.008244:0.004738:0.004738
et  al. :@0.427476:0.181582:0.479887:0.181582:0.479887:0.167577:0.427476:0.167577:0.011118:0.005798:0.004738:0.006178:0.011682:0.003421:0.004738:0.004738
Participants of the MASCC/ESMO Consen-:@0.120589:0.196105:0.475168:0.196105:0.475168:0.182099:0.120589:0.182099:0.010126:0.011682:0.005148:0.005798:0.003421:0.011067:0.003421:0.011665:0.011682:0.010434:0.005798:0.006636:0.005987:0.011203:0.005371:0.005975:0.005798:0.010434:0.011118:0.005978:0.015719:0.012657:0.008518:0.013906:0.013906:0.007475:0.009168:0.008518:0.015719:0.014864:0.005978:0.013906:0.011203:0.010434:0.006636:0.011118:0.010434:0.005679
sus Conference Copenhagen  2015.  2016 :@0.120589:0.210627:0.479878:0.210627:0.479878:0.196622:0.120589:0.196622:0.006636:0.010399:0.006636:0.008997:0.013906:0.011203:0.010434:0.005371:0.011118:0.005077:0.011118:0.010434:0.011067:0.011118:0.008997:0.013906:0.011203:0.011665:0.011118:0.010434:0.010434:0.011682:0.011511:0.011118:0.010434:0.004738:0.004247:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.004269:0.009476:0.009476:0.009476:0.009476:0.004738
MASCC  and ESMO guideline update for :@0.120589:0.225150:0.479909:0.225150:0.479909:0.211145:0.120589:0.211145:0.015719:0.012657:0.008518:0.013906:0.013906:0.004738:0.004678:0.011682:0.010434:0.011716:0.009425:0.009168:0.008518:0.015719:0.014864:0.009425:0.011511:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.009425:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.009425:0.005371:0.011203:0.005148:0.004738
the prevention of chemotherapy- and ra-:@0.120589:0.239673:0.475163:0.239673:0.475163:0.225667:0.120589:0.225667:0.005798:0.010434:0.011118:0.006797:0.011665:0.005082:0.011118:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.006794:0.011203:0.005371:0.006808:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009156:0.005679:0.006808:0.011682:0.010434:0.011716:0.006808:0.005148:0.011682:0.005679
diotherapy-induced nausea and vomiting :@0.120589:0.254195:0.479900:0.254195:0.479900:0.240190:0.120589:0.240190:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005679:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.006859:0.010434:0.011682:0.010399:0.006636:0.011118:0.011682:0.006859:0.011682:0.010434:0.011716:0.006859:0.009476:0.011203:0.016044:0.003421:0.005798:0.003421:0.010434:0.011511:0.004738
in advanced cancer patients. :@0.120589:0.268718:0.378340:0.268718:0.378340:0.254713:0.120589:0.254713:0.003421:0.010434:0.006158:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.006158:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006146:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
Ann Oncol. :@0.379760:0.268718:0.479906:0.268718:0.479906:0.254713:0.379760:0.254713:0.012657:0.010434:0.010434:0.006158:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738:0.004738
2016 Sep;27(suppl 5):v119-v133.:@0.120589:0.283241:0.379806:0.283241:0.379806:0.269235:0.120589:0.269235:0.009476:0.009476:0.009476:0.009476:0.004738:0.008518:0.011118:0.011665:0.004738:0.009476:0.009476:0.006312:0.006636:0.010399:0.011665:0.011665:0.003421:0.004738:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
29.  Einhorn LH, Rapoport  B, Navari RM, :@0.084242:0.297763:0.427525:0.297763:0.427525:0.283758:0.084242:0.283758:0.009476:0.009476:0.004738:0.012657:0.000000:0.009168:0.003421:0.010434:0.010434:0.011203:0.005501:0.010434:0.007817:0.007902:0.011682:0.004738:0.007817:0.010382:0.011682:0.011665:0.011203:0.011665:0.011203:0.005148:0.005798:0.004738:0.003067:0.009818:0.004738:0.007817:0.012657:0.011682:0.009476:0.011682:0.005148:0.003421:0.007817:0.010382:0.015719:0.004738:0.004738
et al. :@0.430589:0.297763:0.479900:0.297763:0.479900:0.283758:0.430589:0.283758:0.011118:0.005798:0.007817:0.011682:0.003421:0.004738:0.004738
2016 updated  MASCC/ESMO consensus :@0.120589:0.312286:0.479892:0.312286:0.479892:0.298281:0.120589:0.298281:0.009476:0.009476:0.009476:0.009476:0.012520:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.011716:0.004738:0.007774:0.015719:0.012657:0.008518:0.013906:0.013906:0.007475:0.009168:0.008518:0.015719:0.014864:0.012520:0.011067:0.011203:0.010434:0.006636:0.011118:0.010434:0.006636:0.010399:0.006636:0.004738
recommendations:  prevention  of nausea :@0.120589:0.326809:0.479894:0.326809:0.479894:0.312803:0.120589:0.312803:0.005078:0.011118:0.011067:0.011203:0.016044:0.016044:0.011118:0.010434:0.011716:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.004738:0.004776:0.011665:0.005080:0.011118:0.009476:0.011118:0.010434:0.005798:0.003421:0.011203:0.010434:0.004738:0.004781:0.011203:0.005371:0.009527:0.010434:0.011682:0.010399:0.006636:0.011118:0.011682:0.004738
and vomiting following multiple-day chem-:@0.120589:0.341331:0.475149:0.341331:0.475149:0.327326:0.120589:0.327326:0.011682:0.010434:0.011716:0.004336:0.009476:0.011203:0.016044:0.003421:0.005798:0.003421:0.010434:0.011511:0.004336:0.005371:0.011203:0.003421:0.003421:0.011203:0.014214:0.003421:0.010434:0.011511:0.004331:0.016044:0.010399:0.003421:0.005798:0.003421:0.011665:0.003421:0.011118:0.005679:0.011716:0.011682:0.009168:0.004345:0.011067:0.010434:0.011118:0.016044:0.005679
otherapy,  high-dose  chemotherapy, and :@0.120589:0.355854:0.479899:0.355854:0.479899:0.341849:0.120589:0.341849:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738:0.004598:0.010434:0.003421:0.011511:0.010434:0.005679:0.011716:0.011203:0.006636:0.011118:0.004738:0.004604:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005130:0.011682:0.011665:0.009168:0.004738:0.009356:0.011682:0.010434:0.011716:0.004738
breakthrough  nausea and vomiting. :@0.120589:0.370377:0.435268:0.370377:0.435268:0.356372:0.120589:0.356372:0.011665:0.005080:0.011118:0.011682:0.008586:0.005798:0.010434:0.005073:0.011203:0.010399:0.011511:0.010434:0.004738:0.003626:0.010434:0.011682:0.010399:0.006636:0.011118:0.011682:0.008381:0.011682:0.010434:0.011716:0.008381:0.009476:0.011203:0.016044:0.003421:0.005798:0.003421:0.010434:0.011511:0.004738:0.004738
Sup-:@0.438884:0.370377:0.475145:0.370377:0.475145:0.356372:0.438884:0.356372:0.008518:0.010399:0.011665:0.005679
port Care Cancer.:@0.120589:0.384899:0.273827:0.384899:0.273827:0.370894:0.120589:0.370894:0.011665:0.011203:0.005148:0.005798:0.004738:0.013906:0.011682:0.005148:0.011118:0.004738:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
 2017 Jan;25(1):303-308:@0.273810:0.384899:0.464609:0.384899:0.464609:0.370894:0.273810:0.370894:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.008244:0.011682:0.010434:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476
.:@0.464643:0.384899:0.469381:0.384899:0.469381:0.370894:0.464643:0.370894:0.004738
30.  Aapro M, Carides A, Rapoport  BL, :@0.084242:0.399422:0.425189:0.399422:0.425189:0.385417:0.084242:0.385417:0.009476:0.009476:0.004738:0.012657:0.000000:0.012657:0.011682:0.011665:0.005078:0.011203:0.008980:0.015719:0.004738:0.008980:0.013906:0.011682:0.005148:0.003421:0.011716:0.011118:0.006636:0.008980:0.012657:0.004738:0.008980:0.010382:0.011682:0.011665:0.011203:0.011665:0.011203:0.005148:0.005798:0.004738:0.004232:0.009818:0.007902:0.004738:0.004738
et al. :@0.429431:0.399422:0.479906:0.399422:0.479906:0.385417:0.429431:0.385417:0.011118:0.005798:0.008980:0.011682:0.003421:0.004738:0.004738
Aprepitant  and  fosaprepitant:  a  10-year :@0.120589:0.413945:0.479882:0.413945:0.479882:0.399940:0.120589:0.399940:0.012657:0.011665:0.005075:0.011118:0.011665:0.003421:0.005798:0.011682:0.010434:0.005798:0.004738:0.005684:0.011682:0.010434:0.011716:0.004738:0.005685:0.005371:0.011203:0.006636:0.011682:0.011665:0.005080:0.011118:0.011665:0.003421:0.005798:0.011682:0.010434:0.005798:0.004738:0.004738:0.005682:0.011682:0.004738:0.005684:0.009476:0.009476:0.005679:0.009168:0.011118:0.011682:0.005148:0.004738
review of efficacy and safety. :@0.120589:0.428468:0.378973:0.428468:0.378973:0.414462:0.120589:0.414462:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.006630:0.011203:0.005371:0.006621:0.011118:0.005371:0.004165:0.004165:0.011067:0.011682:0.011067:0.009168:0.006625:0.011682:0.010434:0.011716:0.006626:0.006636:0.011682:0.005371:0.011118:0.005798:0.009168:0.004738:0.004738
Oncologist. :@0.380866:0.428468:0.479900:0.428468:0.479900:0.414462:0.380866:0.414462:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.006636:0.005798:0.004738:0.004738
2015 Apr;20(4):450-8.:@0.120589:0.442990:0.291547:0.442990:0.291547:0.428985:0.120589:0.428985:0.009476:0.009476:0.009476:0.009476:0.004738:0.012657:0.011665:0.005148:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
31.  Cinausero  M,  Aprile  G,  Ermacora  P, :@0.084242:0.457513:0.428268:0.457513:0.428268:0.443508:0.084242:0.443508:0.009476:0.009476:0.004738:0.012657:0.000000:0.013906:0.003421:0.010434:0.011682:0.010399:0.006636:0.011118:0.005080:0.011203:0.004738:0.002692:0.015719:0.004738:0.004738:0.002691:0.012657:0.011665:0.005148:0.003421:0.003421:0.011118:0.004738:0.002694:0.014915:0.004738:0.004738:0.002692:0.009168:0.005624:0.016044:0.011682:0.011067:0.011203:0.005148:0.011682:0.004738:0.002689:0.008017:0.004738:0.004738
et  al:@0.430965:0.457513:0.470413:0.457513:0.470413:0.443508:0.430965:0.443508:0.011118:0.005798:0.004738:0.002691:0.011682:0.003421
. :@0.470413:0.457513:0.479888:0.457513:0.479888:0.443508:0.470413:0.443508:0.004738:0.004738
New  frontiers  in the  pathobiology  and :@0.120589:0.472036:0.479894:0.472036:0.479894:0.458030:0.120589:0.458030:0.012657:0.011118:0.014214:0.004738:0.008251:0.005371:0.005078:0.011203:0.010434:0.005798:0.003421:0.011118:0.005148:0.006636:0.004738:0.008253:0.003421:0.010434:0.012999:0.005798:0.010434:0.011118:0.004738:0.008249:0.011665:0.011682:0.005798:0.010434:0.011203:0.011665:0.003421:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.008253:0.011682:0.010434:0.011716:0.004738
treatment of cancer regimen-related mu-:@0.120589:0.486558:0.475164:0.486558:0.475164:0.472553:0.120589:0.472553:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.007037:0.011203:0.005371:0.007047:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.007038:0.005078:0.011118:0.011511:0.003421:0.016044:0.011118:0.010434:0.005679:0.005073:0.011118:0.003421:0.011682:0.005798:0.011118:0.011716:0.007047:0.016044:0.010399:0.005679
cosal injury. :@0.120589:0.501081:0.228193:0.501081:0.228193:0.487076:0.120589:0.487076:0.011067:0.011203:0.006636:0.011682:0.003421:0.012076:0.003421:0.010434:0.003472:0.010399:0.005148:0.009168:0.004738:0.004738
Front Pharmacol.:@0.235530:0.501081:0.384010:0.501081:0.384010:0.487076:0.235530:0.487076:0.008296:0.005148:0.011193:0.010434:0.005798:0.012076:0.010126:0.010434:0.011682:0.005148:0.016044:0.011682:0.011067:0.011193:0.003421:0.004738
 2017  Jun :@0.384010:0.501081:0.479894:0.501081:0.479894:0.487076:0.384010:0.487076:0.012076:0.009476:0.009476:0.009476:0.009476:0.004738:0.007351:0.008244:0.010399:0.010434:0.004738
8;8:354.:@0.120589:0.515604:0.182182:0.515604:0.182182:0.501598:0.120589:0.501598:0.009476:0.004738:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738
32.  Eyob T, Ng T, Chan R, :@0.084242:0.530126:0.324824:0.530126:0.324824:0.516121:0.084242:0.516121:0.009476:0.009476:0.004738:0.012657:0.000000:0.009168:0.009168:0.011203:0.011665:0.010399:0.005537:0.004738:0.010399:0.012657:0.011511:0.010399:0.005538:0.004738:0.010399:0.013906:0.010434:0.011682:0.010434:0.010399:0.010382:0.004738:0.004738
et al:@0.330485:0.530126:0.372904:0.530126:0.372904:0.516121:0.330485:0.516121:0.011118:0.005798:0.010399:0.011682:0.003421
. Impact of :@0.372904:0.530126:0.479875:0.530126:0.479875:0.516121:0.372904:0.516121:0.004738:0.010399:0.003866:0.016044:0.011665:0.011682:0.011067:0.005798:0.010399:0.011203:0.005371:0.004738
chemotherapy  on  cancer-related  fatigue :@0.120589:0.544649:0.479900:0.544649:0.479900:0.530644:0.120589:0.530644:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.002800:0.011203:0.010434:0.004738:0.002810:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.005679:0.005071:0.011118:0.003421:0.011682:0.005798:0.011118:0.011716:0.004738:0.002814:0.005371:0.011682:0.005798:0.003421:0.011511:0.010399:0.011118:0.004738
and cytokines in 1312 patients: a systemat-:@0.120589:0.559172:0.475128:0.559172:0.475128:0.545166:0.120589:0.545166:0.011682:0.010434:0.011716:0.004994:0.011067:0.009168:0.005798:0.011203:0.008586:0.003421:0.010434:0.011118:0.006636:0.004994:0.003421:0.010434:0.004994:0.009476:0.009476:0.009476:0.009476:0.005012:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.004994:0.011682:0.004994:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.011682:0.005798:0.005679
ic review of quantitative studies. :@0.120589:0.573694:0.393932:0.573694:0.393932:0.559689:0.120589:0.559689:0.003421:0.011067:0.005490:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.005490:0.011203:0.005371:0.005490:0.011665:0.010399:0.011682:0.010434:0.005798:0.003421:0.005798:0.011682:0.005798:0.003421:0.009476:0.011118:0.005490:0.006636:0.005798:0.010399:0.011716:0.003421:0.011118:0.006636:0.004738:0.004738
Curr Opin :@0.394685:0.573694:0.479887:0.573694:0.479887:0.559689:0.394685:0.559689:0.013906:0.010399:0.005148:0.005148:0.005479:0.014864:0.011665:0.003421:0.010434:0.004738
Support Palliat Care:@0.120589:0.588217:0.285742:0.588217:0.285742:0.574212:0.120589:0.574212:0.008518:0.010399:0.011665:0.011665:0.011203:0.005148:0.005798:0.004669:0.010126:0.011682:0.003421:0.003421:0.003421:0.011682:0.005798:0.004680:0.013906:0.011682:0.005148:0.011118
. 2016 Jun;10(2):165-79.:@0.285742:0.588217:0.475137:0.588217:0.475137:0.574212:0.285742:0.574212:0.004738:0.004669:0.009476:0.009476:0.009476:0.009476:0.004685:0.008244:0.010399:0.010434:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
33.  Chon SY, Champion RW, Geddes ER, :@0.084242:0.602740:0.431704:0.602740:0.431704:0.588734:0.084242:0.588734:0.009476:0.009476:0.004738:0.012657:0.000000:0.013906:0.010434:0.011203:0.010434:0.005716:0.008518:0.008460:0.004738:0.005730:0.013906:0.010434:0.011682:0.016044:0.011665:0.003421:0.011203:0.010434:0.005730:0.010415:0.014607:0.004738:0.005721:0.014915:0.011118:0.011716:0.011716:0.011118:0.006636:0.005730:0.009168:0.010382:0.004738:0.004738
et al:@0.432696:0.602740:0.470435:0.602740:0.470435:0.588734:0.432696:0.588734:0.011118:0.005798:0.005720:0.011682:0.003421
. :@0.470435:0.602740:0.479911:0.602740:0.479911:0.588734:0.470435:0.588734:0.004738:0.004738
Chemotherapy-induced  alopecia. :@0.120589:0.617262:0.420035:0.617262:0.420035:0.603257:0.120589:0.603257:0.013906:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005679:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.004738:0.006705:0.011682:0.003421:0.011203:0.011665:0.011118:0.011067:0.003421:0.011682:0.004738:0.004738
J Am :@0.426757:0.617262:0.479900:0.617262:0.479900:0.603257:0.426757:0.603257:0.008244:0.011460:0.012657:0.016044:0.004738
Acad Dermatol. :@0.120589:0.631785:0.259066:0.631785:0.259066:0.617780:0.120589:0.617780:0.012657:0.011067:0.011682:0.011716:0.004738:0.012726:0.011118:0.005148:0.016044:0.011682:0.005798:0.011203:0.003421:0.004738:0.004738
2012 Jul;67(1):e37-47.:@0.259049:0.631785:0.433719:0.631785:0.433719:0.617780:0.259049:0.617780:0.009476:0.009476:0.009476:0.009476:0.004738:0.008244:0.010399:0.003421:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.011118:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
34.  Dong C, Chen L. Second malignancies af-:@0.084242:0.646308:0.475163:0.646308:0.475163:0.632303:0.084242:0.632303:0.009476:0.009476:0.004738:0.012657:0.000000:0.012726:0.011203:0.010434:0.011511:0.005644:0.013906:0.004738:0.005644:0.013906:0.010434:0.011118:0.010434:0.005644:0.007902:0.004738:0.005644:0.008518:0.011118:0.011067:0.011203:0.010434:0.011716:0.005644:0.016044:0.011682:0.003421:0.003421:0.011511:0.010434:0.011682:0.010434:0.011067:0.003421:0.011118:0.006636:0.005644:0.011682:0.005371:0.005679
ter breast cancer: the impact of adjuvant :@0.120589:0.660830:0.479888:0.660830:0.479888:0.646825:0.120589:0.646825:0.005798:0.011118:0.005148:0.006163:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.006175:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.006161:0.005798:0.010434:0.011118:0.006163:0.003421:0.016044:0.011665:0.011682:0.011067:0.005798:0.006175:0.011203:0.005371:0.006166:0.011682:0.011716:0.003472:0.010399:0.009476:0.011682:0.010434:0.005798:0.004738
therapy. :@0.120589:0.675353:0.195079:0.675353:0.195079:0.661348:0.120589:0.661348:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
Mol Clin Oncol.:@0.193916:0.675353:0.318328:0.675353:0.318328:0.661348:0.193916:0.661348:0.015719:0.011203:0.003421:0.003580:0.013906:0.003421:0.003421:0.010434:0.003582:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2014 May;2(3):331-:@0.318328:0.675353:0.475128:0.675353:0.475128:0.661348:0.318328:0.661348:0.003580:0.009476:0.009476:0.009476:0.009476:0.003592:0.015719:0.011682:0.009168:0.004738:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679
336.:@0.120589:0.689876:0.153755:0.689876:0.153755:0.675871:0.120589:0.675871:0.009476:0.009476:0.009476:0.004738
35.  Hijiya N, Hudson MM, Lensing S, :@0.084242:0.704399:0.376159:0.704399:0.376159:0.690393:0.084242:0.690393:0.009476:0.009476:0.004738:0.012657:0.000000:0.011682:0.003421:0.003472:0.003421:0.009168:0.011682:0.003537:0.012657:0.004738:0.003523:0.011682:0.010399:0.011716:0.006636:0.011203:0.010434:0.003523:0.015719:0.015719:0.004738:0.003523:0.007902:0.011118:0.010434:0.006636:0.003421:0.010434:0.011511:0.003523:0.008518:0.004738:0.004738
et al:@0.374945:0.704399:0.410488:0.704399:0.410488:0.690393:0.374945:0.690393:0.011118:0.005798:0.003523:0.011682:0.003421
. Cumu-:@0.410488:0.704399:0.475176:0.704399:0.475176:0.690393:0.410488:0.690393:0.004738:0.003523:0.013906:0.010399:0.016044:0.010399:0.005679
lative incidence of secondary neoplasms as :@0.120589:0.718921:0.479895:0.718921:0.479895:0.704916:0.120589:0.704916:0.003421:0.011682:0.005798:0.003421:0.009476:0.011118:0.002788:0.003421:0.010434:0.011067:0.003421:0.011716:0.011118:0.010434:0.011067:0.011118:0.002788:0.011203:0.005371:0.002788:0.006636:0.011118:0.011067:0.011203:0.010434:0.011716:0.011682:0.005148:0.009168:0.002788:0.010434:0.011118:0.011203:0.011665:0.003421:0.011682:0.006636:0.016044:0.006636:0.002800:0.011682:0.006636:0.004738
a first event after childhood acute lympho-:@0.120589:0.733444:0.475161:0.733444:0.475161:0.719439:0.120589:0.719439:0.011682:0.004608:0.004165:0.004165:0.005148:0.006636:0.005798:0.004599:0.011118:0.009476:0.011118:0.010434:0.005798:0.004601:0.011682:0.005371:0.005798:0.011118:0.005148:0.004606:0.011067:0.010434:0.003421:0.003421:0.011716:0.010434:0.011203:0.011203:0.011716:0.004601:0.011682:0.011067:0.010399:0.005798:0.011118:0.004606:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.005679
blastic leukemia.:@0.120589:0.747967:0.263565:0.747967:0.263565:0.733961:0.120589:0.733961:0.011665:0.003421:0.011682:0.006636:0.005798:0.003421:0.011067:0.008757:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.004738
  JAMA. :@0.263565:0.747967:0.331065:0.747967:0.331065:0.733961:0.263565:0.733961:0.004738:0.004009:0.008244:0.012657:0.015719:0.012657:0.004738:0.004738
2007 Mar  21;297 :@0.335061:0.747967:0.479883:0.747967:0.479883:0.733961:0.335061:0.733961:0.009476:0.009476:0.009476:0.009476:0.008757:0.015719:0.011682:0.005148:0.004738:0.004006:0.009476:0.009476:0.004738:0.009476:0.009476:0.009489:0.004738
(11):1207-15.:@0.120589:0.762489:0.224173:0.762489:0.224173:0.748484:0.120589:0.748484:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
36.  Oktay K, Harvey BE, Partridge AH, :@0.084242:0.777012:0.399452:0.777012:0.399452:0.763007:0.084242:0.763007:0.009476:0.009476:0.004738:0.012657:0.000000:0.014864:0.008586:0.005798:0.011682:0.009168:0.004490:0.010109:0.004738:0.004481:0.011682:0.011682:0.005148:0.009476:0.011118:0.009168:0.004498:0.009818:0.009168:0.004738:0.004490:0.010126:0.011682:0.005148:0.005798:0.005148:0.003421:0.011716:0.011511:0.011106:0.004486:0.012657:0.011682:0.004738:0.004738
et al:@0.399185:0.777012:0.435687:0.777012:0.435687:0.763007:0.399185:0.763007:0.011118:0.005798:0.004483:0.011682:0.003421
. Fer-:@0.435687:0.777012:0.475145:0.777012:0.475145:0.763007:0.435687:0.763007:0.004738:0.004485:0.008296:0.011118:0.005143:0.005679
tility  preservation in patients with cancer: :@0.120589:0.791535:0.479894:0.791535:0.479894:0.777529:0.120589:0.777529:0.005798:0.003421:0.003421:0.003421:0.005798:0.009168:0.004738:0.003517:0.011665:0.005080:0.011118:0.006636:0.011118:0.005148:0.009476:0.011682:0.005798:0.003421:0.011203:0.010434:0.008244:0.003421:0.010434:0.008244:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.008244:0.014214:0.003421:0.005798:0.010434:0.008244:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738
ASCO clinical  practice guideline update.  :@0.120589:0.806057:0.479883:0.806057:0.479883:0.792052:0.120589:0.792052:0.012657:0.008518:0.013906:0.014864:0.008005:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.003284:0.011665:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.008005:0.011511:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.008005:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.004738:0.000000:0.004738
J Clin Oncol.:@0.120589:0.820580:0.225217:0.820580:0.225217:0.806575:0.120589:0.806575:0.008244:0.004738:0.013906:0.003421:0.003421:0.010434:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2018 Apr 5:JCO2018781914.:@0.225217:0.820580:0.457528:0.820580:0.457528:0.806575:0.225217:0.806575:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.012657:0.011665:0.005148:0.004738:0.009476:0.004738:0.008244:0.013906:0.014864:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.009476:0.004738
37.  Brydøy M, Fosså SD, Dahl O, :@0.084242:0.835103:0.353898:0.835103:0.353898:0.821097:0.084242:0.821097:0.009476:0.009476:0.004738:0.012657:0.000000:0.009818:0.005148:0.009168:0.011716:0.011169:0.009168:0.004721:0.015719:0.004738:0.004721:0.008296:0.011203:0.006636:0.006636:0.011682:0.004733:0.008518:0.012726:0.004738:0.004721:0.012726:0.011682:0.010434:0.003421:0.004731:0.014864:0.004738:0.004738
et al:@0.353881:0.835103:0.390621:0.835103:0.390621:0.821097:0.353881:0.821097:0.011118:0.005798:0.004721:0.011682:0.003421
. Gonadal :@0.390621:0.835103:0.479871:0.835103:0.479871:0.821097:0.390621:0.821097:0.004738:0.004721:0.014915:0.011203:0.010434:0.011682:0.011716:0.011682:0.003421:0.004738
dysfunction and fertility problems in cancer :@0.120589:0.849625:0.479883:0.849625:0.479883:0.835620:0.120589:0.835620:0.011716:0.009168:0.006636:0.005371:0.010399:0.010434:0.011067:0.005798:0.003421:0.011203:0.010434:0.004242:0.011682:0.010434:0.011716:0.004242:0.005371:0.011118:0.005148:0.005798:0.003421:0.003421:0.003421:0.005798:0.009168:0.004242:0.011665:0.005080:0.011203:0.011665:0.003421:0.011118:0.016044:0.006636:0.004242:0.003421:0.010434:0.004242:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
survivors. :@0.120589:0.864148:0.197610:0.864148:0.197610:0.850143:0.120589:0.850143:0.006636:0.010399:0.005148:0.009476:0.003421:0.009476:0.011203:0.005148:0.006636:0.004738:0.004738
Acta Oncol.:@0.197610:0.864148:0.299278:0.864148:0.299278:0.850143:0.197610:0.850143:0.012657:0.011067:0.005798:0.011682:0.004738:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2007;46(4):480-9.:@0.299261:0.864148:0.440749:0.864148:0.440749:0.850143:0.299261:0.850143:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.004738
38.  Van Dorp W, van Beek RD, Laven JS, :@0.084242:0.878671:0.431310:0.878671:0.431310:0.864665:0.084242:0.864665:0.009476:0.009476:0.004738:0.012657:0.000000:0.010232:0.011682:0.010434:0.005908:0.012726:0.011203:0.005148:0.011665:0.005908:0.014607:0.004738:0.005908:0.009476:0.011682:0.010434:0.005908:0.009818:0.011118:0.011118:0.008586:0.005910:0.010382:0.012726:0.004738:0.005908:0.007902:0.011682:0.009476:0.011118:0.010434:0.005910:0.008244:0.008518:0.004738:0.004738
et al:@0.432487:0.878671:0.470413:0.878671:0.470413:0.864665:0.432487:0.864665:0.011118:0.005798:0.005906:0.011682:0.003421
. :@0.470413:0.878671:0.479888:0.878671:0.479888:0.864665:0.470413:0.864665:0.004738:0.004738
Long-term endocrine side effects of child-:@0.120589:0.892899:0.475164:0.892899:0.475164:0.878894:0.120589:0.878894:0.007902:0.011203:0.010434:0.011511:0.005679:0.005798:0.011118:0.005607:0.016044:0.006380:0.011118:0.010434:0.011716:0.011203:0.011067:0.005148:0.003421:0.010434:0.011118:0.006380:0.006636:0.003421:0.011716:0.011118:0.006380:0.011118:0.005419:0.005371:0.011118:0.011067:0.005798:0.006636:0.006380:0.011203:0.005371:0.006371:0.011067:0.010434:0.003421:0.003421:0.011716:0.005679
hood  Hodgkin’s lymphoma treatment:  a :@0.120589:0.907128:0.479887:0.907128:0.479887:0.893123:0.120589:0.893123:0.010434:0.011203:0.011203:0.011716:0.004738:0.005222:0.011682:0.011203:0.011716:0.011511:0.008586:0.003421:0.010434:0.006004:0.006636:0.009972:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.009972:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.004738:0.005220:0.011682:0.004738
review. :@0.120589:0.921357:0.184489:0.921357:0.184489:0.907352:0.120589:0.907352:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.004738:0.004738
Hum  Reprod  Update. :@0.190580:0.921357:0.384261:0.921357:0.384261:0.907352:0.190580:0.907352:0.011682:0.010399:0.016044:0.004738:0.006098:0.010382:0.011118:0.011665:0.005148:0.011203:0.011716:0.004738:0.006089:0.011203:0.011665:0.011716:0.011682:0.005798:0.011118:0.004738:0.004738
2012 Jan-:@0.390359:0.921357:0.475145:0.921357:0.475145:0.907352:0.390359:0.907352:0.009476:0.009476:0.009476:0.009476:0.010844:0.008244:0.011682:0.010434:0.005679
Feb;18(1):12-28.:@0.120589:0.935586:0.250514:0.935586:0.250514:0.921580:0.120589:0.921580:0.008296:0.011118:0.011665:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
39.  Ngu SF, Ngan HY. Chemotherapy in preg-:@0.523636:0.094411:0.914550:0.094411:0.914550:0.080405:0.523636:0.080405:0.009476:0.009476:0.004738:0.012657:0.000000:0.012657:0.011511:0.010399:0.007028:0.008518:0.006207:0.004738:0.007035:0.012657:0.011511:0.011682:0.010434:0.007030:0.011682:0.009012:0.004738:0.007035:0.013906:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.007026:0.003421:0.010434:0.007038:0.011665:0.005080:0.011118:0.011511:0.005679
nancy. :@0.559983:0.108686:0.622243:0.108686:0.622243:0.094681:0.559983:0.094681:0.010434:0.011682:0.010434:0.011067:0.009168:0.004738:0.004738
Best Pract Res Clin Obstet Gynae-:@0.624449:0.108686:0.914546:0.108686:0.914546:0.094681:0.624449:0.094681:0.009818:0.011118:0.006636:0.005798:0.006944:0.010126:0.005148:0.011682:0.011067:0.005798:0.006934:0.010382:0.011118:0.006636:0.006944:0.013906:0.003421:0.003421:0.010434:0.006944:0.014864:0.011665:0.006636:0.005798:0.011118:0.005798:0.006944:0.014915:0.009168:0.010434:0.011682:0.011118:0.005679
col:@0.559983:0.122962:0.585674:0.122962:0.585674:0.108957:0.559983:0.108957:0.011067:0.011203:0.003421
. 2016 May;33:86-101.:@0.585674:0.122962:0.760583:0.122962:0.760583:0.108957:0.585674:0.108957:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.015719:0.011682:0.009168:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
40.  Rivera DR, Ganz PA,  Weyrich MS, :@0.523636:0.137238:0.861618:0.137238:0.861618:0.123232:0.523636:0.123232:0.009476:0.009476:0.004738:0.012657:0.000000:0.010382:0.003421:0.009476:0.011118:0.005148:0.011682:0.010468:0.012726:0.010382:0.004738:0.010468:0.014915:0.011682:0.010434:0.007269:0.010468:0.008852:0.012657:0.004738:0.004738:0.005720:0.015618:0.011118:0.009168:0.005148:0.003421:0.011067:0.010434:0.010468:0.015719:0.008518:0.004738:0.004738
et  al:@0.867348:0.137238:0.909827:0.137238:0.909827:0.123232:0.867348:0.123232:0.011118:0.005798:0.004738:0.005721:0.011682:0.003421
. :@0.909827:0.137238:0.919303:0.137238:0.919303:0.123232:0.909827:0.123232:0.004738:0.004738
Chemotherapy-associated peripheral neu-:@0.559983:0.151513:0.914556:0.151513:0.914556:0.137508:0.559983:0.137508:0.013906:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005679:0.011682:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005798:0.011118:0.011716:0.003883:0.011665:0.011118:0.005148:0.003421:0.011665:0.010434:0.011118:0.005148:0.011682:0.003421:0.003883:0.010434:0.011118:0.010399:0.005679
ropathy in patients with early-stage breast :@0.559983:0.165789:0.919276:0.165789:0.919276:0.151784:0.559983:0.151784:0.005078:0.011203:0.011665:0.011682:0.005798:0.010434:0.009168:0.006060:0.003421:0.010434:0.006063:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.006063:0.014214:0.003421:0.005798:0.010434:0.006062:0.011118:0.011682:0.005148:0.003421:0.009168:0.005679:0.006636:0.005798:0.011682:0.011511:0.011118:0.006060:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.004738
cancer: a systematic review. :@0.559983:0.180065:0.801158:0.180065:0.801158:0.166060:0.559983:0.166060:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004315:0.011682:0.004327:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.011682:0.005798:0.003421:0.011067:0.004327:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.004738:0.004738
J Natl Cancer :@0.800747:0.180065:0.919298:0.180065:0.919298:0.166060:0.800747:0.166060:0.008244:0.004327:0.012657:0.011682:0.005798:0.003421:0.004327:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
Inst.:@0.559983:0.194341:0.591455:0.194341:0.591455:0.180335:0.559983:0.180335:0.003866:0.010434:0.006636:0.005798:0.004738
 2018 Feb 1;110(2).:@0.591455:0.194341:0.744129:0.194341:0.744129:0.180335:0.591455:0.180335:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.008296:0.011118:0.011665:0.004738:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738
41.  Argyriou AA,  Bruna J, Marmiroli P, :@0.523636:0.208616:0.862451:0.208616:0.862451:0.194611:0.523636:0.194611:0.009476:0.009476:0.004738:0.012657:0.000000:0.012657:0.005148:0.011511:0.009168:0.005148:0.003421:0.011203:0.010399:0.010040:0.012657:0.012657:0.004738:0.004738:0.005290:0.009818:0.005148:0.010399:0.010434:0.011682:0.010040:0.008244:0.004738:0.010040:0.015719:0.011682:0.005622:0.016044:0.003421:0.005080:0.011203:0.003421:0.003421:0.010040:0.008017:0.004738:0.004738
et al:@0.867754:0.208616:0.909813:0.208616:0.909813:0.194611:0.867754:0.194611:0.011118:0.005798:0.010040:0.011682:0.003421
. :@0.909813:0.208616:0.919289:0.208616:0.919289:0.194611:0.909813:0.194611:0.004738:0.004738
Chemotherapy-induced peripheral neuro-:@0.559983:0.222892:0.914550:0.222892:0.914550:0.208887:0.559983:0.208887:0.013906:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005679:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.006279:0.011665:0.011118:0.005148:0.003421:0.011665:0.010434:0.011118:0.005148:0.011682:0.003421:0.006294:0.010434:0.011118:0.010399:0.005071:0.011203:0.005679
toxicity (CIPN): an update. :@0.559983:0.237168:0.789506:0.237168:0.789506:0.223163:0.559983:0.223163:0.005798:0.011203:0.008210:0.003421:0.011067:0.003421:0.005798:0.009168:0.006517:0.006312:0.013906:0.003866:0.010126:0.012657:0.006312:0.004738:0.006517:0.011682:0.010434:0.006517:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.004738:0.004738
Crit Rev Oncol :@0.791285:0.237168:0.919294:0.237168:0.919294:0.223163:0.791285:0.223163:0.013906:0.005148:0.003421:0.005798:0.006517:0.010382:0.011118:0.009476:0.006517:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
Hematol.:@0.559983:0.251444:0.635670:0.251444:0.635670:0.237438:0.559983:0.237438:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.004738
 2012 Apr;82(1):51-77.:@0.635670:0.251444:0.811366:0.251444:0.811366:0.237438:0.635670:0.237438:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.012657:0.011665:0.005148:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
42.  Argyriou  AA,  Cavaletti G,  Bruna  J, :@0.523636:0.266013:0.864625:0.266013:0.864625:0.252008:0.523636:0.252008:0.009476:0.009476:0.004738:0.012657:0.000000:0.012657:0.005148:0.011511:0.009168:0.005148:0.003421:0.011203:0.010399:0.004738:0.004225:0.012657:0.012657:0.004738:0.004738:0.004206:0.013906:0.011682:0.009476:0.011682:0.003421:0.011118:0.005798:0.005798:0.003421:0.008963:0.014915:0.004738:0.004738:0.004216:0.009818:0.005148:0.010399:0.010434:0.011682:0.004738:0.004215:0.008244:0.004738:0.004738
et  al:@0.868836:0.266013:0.909807:0.266013:0.909807:0.252008:0.868836:0.252008:0.011118:0.005798:0.004738:0.004213:0.011682:0.003421
. :@0.909807:0.266013:0.919282:0.266013:0.919282:0.252008:0.909807:0.252008:0.004738:0.004738
Bortezomib-induced peripheral neurotoxic-:@0.559983:0.280583:0.914556:0.280583:0.914556:0.266578:0.559983:0.266578:0.009818:0.011203:0.005148:0.005798:0.011118:0.007269:0.011203:0.016044:0.003421:0.011665:0.005679:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.003948:0.011665:0.011118:0.005148:0.003421:0.011665:0.010434:0.011118:0.005148:0.011682:0.003421:0.003958:0.010434:0.011118:0.010399:0.005077:0.011203:0.005798:0.011203:0.008210:0.003421:0.011067:0.005679
ity: an update. :@0.559983:0.295153:0.684617:0.295153:0.684617:0.281148:0.559983:0.281148:0.003421:0.005798:0.009168:0.004738:0.003770:0.011682:0.010434:0.003768:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.004738:0.004738
Arch Toxicol.:@0.683648:0.295153:0.787261:0.295153:0.787261:0.281148:0.683648:0.281148:0.012657:0.005140:0.011067:0.010434:0.003766:0.007286:0.011203:0.008210:0.003421:0.011067:0.011203:0.003421:0.004738
 2014 Sep;88(9): :@0.787261:0.295153:0.919277:0.295153:0.919277:0.281148:0.787261:0.281148:0.003768:0.009476:0.009476:0.009476:0.009476:0.003780:0.008518:0.011118:0.011665:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.004738
1669-79.:@0.559983:0.309723:0.627255:0.309723:0.627255:0.295717:0.559983:0.295717:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
43.  Miltenburg NC, Boogerd W. Chemothera-:@0.523636:0.324292:0.914539:0.324292:0.914539:0.310287:0.523636:0.310287:0.009476:0.009476:0.004738:0.012657:0.000000:0.015719:0.003421:0.003421:0.005798:0.011118:0.010434:0.011665:0.010399:0.005162:0.011511:0.007646:0.012657:0.013906:0.004738:0.007646:0.009818:0.011203:0.011203:0.011511:0.011118:0.005036:0.011716:0.007646:0.015149:0.004738:0.007646:0.013906:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011650:0.005679
py-induced neuropathy: a comprehensive :@0.559983:0.338862:0.919276:0.338862:0.919276:0.324857:0.559983:0.324857:0.011665:0.009168:0.005679:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.005330:0.010434:0.011118:0.010399:0.005071:0.011203:0.011665:0.011682:0.005798:0.010434:0.009168:0.004738:0.005319:0.011682:0.005319:0.011067:0.011203:0.016044:0.011665:0.005077:0.011118:0.010434:0.011118:0.010434:0.006636:0.003421:0.009476:0.011118:0.004738
survey. :@0.559983:0.353432:0.621405:0.353432:0.621405:0.339426:0.559983:0.339426:0.006636:0.010399:0.005148:0.009476:0.011118:0.009168:0.004738:0.004738
Cancer Treat Rev:@0.623628:0.353432:0.772893:0.353432:0.772893:0.339426:0.623628:0.339426:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.006950:0.007286:0.005148:0.011118:0.011682:0.005798:0.006951:0.010382:0.011118:0.009476
. 2014 Aug;40(7): :@0.772893:0.353432:0.919281:0.353432:0.919281:0.339426:0.772893:0.339426:0.004738:0.006953:0.009476:0.009476:0.009476:0.009476:0.006961:0.012657:0.010399:0.011511:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.004738
872-82.:@0.559983:0.368001:0.617779:0.368001:0.617779:0.353996:0.559983:0.353996:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
44.  Brouwers  EE, Huitema AD,  Boogerd W, :@0.523636:0.382571:0.894091:0.382571:0.894091:0.368566:0.523636:0.368566:0.009476:0.009476:0.004738:0.012657:0.000000:0.009818:0.005082:0.011203:0.010399:0.014214:0.011118:0.005148:0.006636:0.004738:0.003547:0.009168:0.009168:0.004738:0.008296:0.011682:0.010399:0.003421:0.005798:0.011118:0.016044:0.011682:0.008296:0.012657:0.012726:0.004738:0.004738:0.003549:0.009818:0.011203:0.011203:0.011511:0.011118:0.005037:0.011716:0.008296:0.014607:0.004738:0.004738
et :@0.897649:0.382571:0.919303:0.382571:0.919303:0.368566:0.897649:0.368566:0.011118:0.005798:0.004738
al:@0.559983:0.397141:0.575086:0.397141:0.575086:0.383136:0.559983:0.383136:0.011682:0.003421
. Persistent neuropathy after treatment :@0.575086:0.397141:0.919305:0.397141:0.919305:0.383136:0.575086:0.383136:0.004738:0.009886:0.010126:0.011118:0.005148:0.006636:0.003421:0.006636:0.005798:0.011118:0.010434:0.005798:0.009886:0.010434:0.011118:0.010399:0.005075:0.011203:0.011665:0.011682:0.005798:0.010434:0.009168:0.009886:0.011682:0.005371:0.005798:0.011118:0.005148:0.009886:0.005798:0.005078:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
with cisplatin and oxaliplatin. :@0.559983:0.411711:0.809023:0.411711:0.809023:0.397705:0.559983:0.397705:0.014214:0.003421:0.005798:0.010434:0.006654:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.006654:0.011682:0.010434:0.011716:0.006654:0.011203:0.008210:0.011682:0.003421:0.003421:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738:0.004738
Acta Oncol.:@0.810972:0.411711:0.914556:0.411711:0.914556:0.397705:0.810972:0.397705:0.012657:0.011067:0.005798:0.011682:0.006654:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 :@0.914556:0.411711:0.919294:0.411711:0.919294:0.397705:0.914556:0.397705:0.004738
2009;48(6):832-41.:@0.559983:0.426280:0.706208:0.426280:0.706208:0.412275:0.559983:0.412275:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
45.  Bakogeorgos  M,  Georgoulias V. Risk-re-:@0.523636:0.440850:0.914548:0.440850:0.914548:0.426845:0.523636:0.426845:0.009476:0.009476:0.004738:0.012657:0.000000:0.009818:0.011682:0.008586:0.011203:0.011511:0.011118:0.011203:0.005148:0.011511:0.011203:0.006636:0.004738:0.008202:0.015719:0.004738:0.004738:0.008200:0.014915:0.011118:0.011203:0.005159:0.011511:0.011203:0.010399:0.003421:0.003421:0.011682:0.006636:0.012948:0.010723:0.004738:0.012948:0.010382:0.003421:0.006636:0.008586:0.005679:0.005082:0.011118:0.005679
duction and treatment of chemotherapy-:@0.559983:0.455420:0.914555:0.455420:0.914555:0.441414:0.559983:0.441414:0.011716:0.010399:0.011067:0.005798:0.003421:0.011203:0.010434:0.006674:0.011682:0.010434:0.011716:0.006688:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.006672:0.011203:0.005371:0.006676:0.011067:0.010434:0.011118:0.016044:0.011195:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005679
induced peripheral neuropathy. :@0.559983:0.469989:0.852495:0.469989:0.852495:0.455984:0.559983:0.455984:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.015685:0.011665:0.011118:0.005148:0.003421:0.011665:0.010434:0.011118:0.005148:0.011682:0.003421:0.015685:0.010434:0.011118:0.010399:0.005073:0.011203:0.011665:0.011682:0.005798:0.010434:0.009168:0.004738:0.004738
Expert :@0.863442:0.469989:0.919288:0.469989:0.919288:0.455984:0.863442:0.455984:0.009168:0.008210:0.011665:0.011118:0.005148:0.005798:0.004738
Rev Anticancer Ther:@0.559983:0.484559:0.726366:0.484559:0.726366:0.470554:0.559983:0.470554:0.010382:0.011118:0.009476:0.004302:0.012657:0.010434:0.005798:0.003421:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004293:0.007286:0.010434:0.011118:0.005148
. 2017 Nov;17(11):1045-:@0.726366:0.484559:0.914534:0.484559:0.914534:0.470554:0.726366:0.470554:0.004738:0.004297:0.009476:0.009476:0.009476:0.009476:0.004310:0.012657:0.011203:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679
1060.:@0.559983:0.499129:0.602624:0.499129:0.602624:0.485124:0.559983:0.485124:0.009476:0.009476:0.009476:0.009476:0.004738
46.  Cheson BD. Etiology and management of :@0.523636:0.513699:0.919289:0.513699:0.919289:0.499693:0.523636:0.499693:0.009476:0.009476:0.004738:0.012657:0.000000:0.013906:0.010434:0.011118:0.006636:0.011203:0.010434:0.006474:0.009818:0.012726:0.004738:0.006483:0.009168:0.005798:0.003421:0.011203:0.003421:0.011203:0.011511:0.009168:0.006483:0.011682:0.010434:0.011716:0.006483:0.016044:0.011682:0.010434:0.011682:0.011511:0.011118:0.016044:0.011118:0.010434:0.005798:0.006469:0.011203:0.005371:0.004738
tumor lysis syndrome in patients with chron-:@0.559983:0.528268:0.914541:0.528268:0.914541:0.514263:0.559983:0.514263:0.005798:0.010399:0.016044:0.011203:0.005148:0.004516:0.003421:0.009168:0.006636:0.003421:0.006636:0.004536:0.006636:0.009168:0.010434:0.011716:0.005082:0.011203:0.016044:0.011118:0.004516:0.003421:0.010434:0.004516:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004516:0.014214:0.003421:0.005798:0.010434:0.004516:0.011067:0.010434:0.005077:0.011203:0.010434:0.005679
ic lymphocytic leukemia. :@0.559983:0.542838:0.770640:0.542838:0.770640:0.528833:0.559983:0.528833:0.003421:0.011067:0.004225:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.011067:0.009168:0.005798:0.003421:0.011067:0.004225:0.003421:0.011118:0.010399:0.008586:0.011118:0.016044:0.003421:0.011682:0.004738:0.004738
Clin Adv Hematol :@0.770127:0.542838:0.919294:0.542838:0.919294:0.528833:0.770127:0.528833:0.013906:0.003421:0.003421:0.010434:0.004225:0.012657:0.011716:0.009476:0.004225:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.004738
Oncol.:@0.559983:0.557408:0.615709:0.557408:0.615709:0.543403:0.559983:0.543403:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
 2009 Apr;7(4):263-71.:@0.615709:0.557408:0.791405:0.557408:0.791405:0.543403:0.615709:0.543403:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.012657:0.011665:0.005148:0.004738:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
47.  Wagner  J, Arora  S. Oncologic metabolic :@0.523636:0.571978:0.919306:0.571978:0.919306:0.557972:0.523636:0.557972:0.009476:0.009476:0.004738:0.012657:0.000000:0.015568:0.011682:0.011511:0.010434:0.011118:0.005148:0.004738:0.003955:0.008244:0.004738:0.008706:0.012657:0.005078:0.011203:0.005148:0.011682:0.004738:0.003958:0.008518:0.004738:0.008706:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.008706:0.016044:0.011118:0.005798:0.011682:0.011665:0.011203:0.003421:0.003421:0.011067:0.004738
emergencies. :@0.559983:0.586547:0.678202:0.586547:0.678202:0.572542:0.559983:0.572542:0.011118:0.016044:0.011118:0.005159:0.011511:0.011118:0.010434:0.011067:0.003421:0.011118:0.006636:0.004738:0.004738
Hematol Oncol Clin North :@0.684144:0.586547:0.919311:0.586547:0.919311:0.572542:0.684144:0.572542:0.011682:0.011118:0.016044:0.011682:0.005798:0.011203:0.003421:0.010690:0.014864:0.010434:0.011067:0.011203:0.003421:0.010690:0.013906:0.003421:0.003421:0.010434:0.010690:0.012657:0.011203:0.005148:0.005798:0.010434:0.004738
Am:@0.559983:0.601117:0.588684:0.601117:0.588684:0.587112:0.559983:0.587112:0.012657:0.016044
. 2017 Dec;31(6):941-957.:@0.588684:0.601117:0.793509:0.601117:0.793509:0.587112:0.588684:0.587112:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.012726:0.011118:0.011067:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
48.  Jain D, Russell RR, Schwartz RG, :@0.523636:0.615687:0.827933:0.615687:0.827933:0.601681:0.523636:0.601681:0.009476:0.009476:0.004738:0.012657:0.000000:0.008244:0.011682:0.003421:0.010434:0.006055:0.012726:0.004738:0.006055:0.010382:0.010399:0.006636:0.006636:0.011118:0.003421:0.003421:0.006065:0.010382:0.010382:0.004738:0.006055:0.008518:0.011067:0.010434:0.014214:0.011682:0.005148:0.005798:0.007269:0.006055:0.010382:0.014915:0.004738:0.004738
et al:@0.829250:0.615687:0.867324:0.615687:0.867324:0.601681:0.829250:0.601681:0.011118:0.005798:0.006055:0.011682:0.003421
. Car-:@0.867324:0.615687:0.914533:0.615687:0.914533:0.601681:0.867324:0.601681:0.004738:0.006055:0.013906:0.011682:0.005148:0.005679
diac complications  of  cancer  therapy: :@0.559983:0.630256:0.919298:0.630256:0.919298:0.616251:0.559983:0.616251:0.011716:0.003421:0.011682:0.011067:0.013205:0.011067:0.011203:0.016044:0.011665:0.003421:0.003421:0.011067:0.011682:0.005798:0.003433:0.011203:0.010434:0.006636:0.004738:0.008455:0.011203:0.005371:0.004738:0.008453:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.008450:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
pathophysiology,  identification,  preven-:@0.559983:0.644826:0.914546:0.644826:0.914546:0.630821:0.559983:0.630821:0.011665:0.011682:0.005798:0.010434:0.011203:0.011665:0.010434:0.009168:0.006636:0.003421:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738:0.012296:0.003421:0.011716:0.011118:0.010434:0.005798:0.003421:0.004165:0.004165:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.004738:0.012289:0.011665:0.005080:0.011118:0.009476:0.011118:0.010434:0.005679
tion, treatment, and future directions. :@0.559983:0.659396:0.878670:0.659396:0.878670:0.645391:0.559983:0.645391:0.005798:0.003421:0.011203:0.010434:0.004738:0.006028:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.006024:0.011682:0.010434:0.011716:0.006038:0.005371:0.010399:0.005798:0.010399:0.005071:0.011118:0.006038:0.011716:0.003421:0.005082:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738:0.004738
Curr :@0.879970:0.659396:0.919310:0.659396:0.919310:0.645391:0.879970:0.645391:0.013906:0.010399:0.005148:0.005148:0.004738
Cardiol Rep:@0.559983:0.673966:0.658384:0.673966:0.658384:0.659960:0.559983:0.659960:0.013906:0.011682:0.005148:0.011716:0.003421:0.011203:0.003421:0.004738:0.010382:0.011118:0.011665
. 2017 May;19(5):36.:@0.658384:0.673966:0.821286:0.673966:0.821286:0.659960:0.658384:0.659960:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.015719:0.011682:0.009168:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.004738
49.  Clasen SC, Wald  JW. Left ventricular dys-:@0.523636:0.688535:0.914529:0.688535:0.914529:0.674530:0.523636:0.674530:0.009476:0.009476:0.004738:0.012657:0.000000:0.013906:0.003421:0.011682:0.006636:0.011118:0.010434:0.008193:0.008518:0.013906:0.004738:0.008193:0.015567:0.011682:0.003421:0.011716:0.004738:0.003465:0.008244:0.015149:0.004738:0.008193:0.007902:0.011118:0.005371:0.005798:0.008193:0.009476:0.011118:0.010434:0.005798:0.005148:0.003421:0.011067:0.010399:0.003421:0.011682:0.005148:0.008193:0.011716:0.009168:0.006636:0.005679
function  and chemotherapeutic  agents. :@0.559983:0.703105:0.919289:0.703105:0.919289:0.689100:0.559983:0.689100:0.005371:0.010399:0.010434:0.011067:0.005798:0.003421:0.011203:0.010434:0.004738:0.006320:0.011682:0.010434:0.011716:0.011067:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.011118:0.010399:0.005798:0.003421:0.011067:0.004738:0.006315:0.011682:0.011511:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
Curr Cardiol Rep:@0.559983:0.717675:0.697724:0.717675:0.697724:0.703669:0.559983:0.703669:0.013906:0.010399:0.005148:0.005148:0.004738:0.013906:0.011682:0.005148:0.011716:0.003421:0.011203:0.003421:0.004738:0.010382:0.011118:0.011665
. 2018 Mar 8;20(4):20.:@0.697707:0.717675:0.870803:0.717675:0.870803:0.703669:0.697707:0.703669:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.015719:0.011682:0.005148:0.004738:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.004738
50.  Marty M, Espié M, Llombart A, :@0.523636:0.732244:0.812016:0.732244:0.812016:0.718239:0.523636:0.718239:0.009476:0.009476:0.004738:0.012657:0.000000:0.015719:0.011682:0.005148:0.005798:0.009168:0.005319:0.015719:0.004738:0.005319:0.009168:0.006636:0.011665:0.003421:0.011118:0.005319:0.015719:0.004738:0.005319:0.007902:0.003421:0.011203:0.016044:0.011665:0.011682:0.005148:0.005798:0.005319:0.012657:0.004738:0.004738
et al.:@0.812597:0.732244:0.854674:0.732244:0.854674:0.718239:0.812597:0.718239:0.011118:0.005798:0.005319:0.011682:0.003421:0.004738
 Dexra-:@0.854674:0.732244:0.914556:0.732244:0.914556:0.718239:0.854674:0.718239:0.005319:0.012726:0.011118:0.008210:0.005148:0.011682:0.005679
zoxane Study Group. Multicenter rand-:@0.559983:0.746814:0.914555:0.746814:0.914555:0.732809:0.559983:0.732809:0.007269:0.011203:0.008210:0.011682:0.010434:0.011118:0.013239:0.008518:0.005798:0.010399:0.011716:0.009168:0.013239:0.014915:0.005078:0.011203:0.010399:0.011665:0.004738:0.013239:0.015719:0.010399:0.003421:0.005798:0.003421:0.011067:0.011118:0.010434:0.005798:0.011118:0.005148:0.013239:0.005148:0.011682:0.010434:0.011716:0.005679
omized phase III study of the cardioprotec-:@0.559983:0.761384:0.914539:0.761384:0.914539:0.747379:0.559983:0.747379:0.011203:0.016044:0.003421:0.007269:0.011118:0.011716:0.004550:0.011665:0.010434:0.011682:0.006636:0.011118:0.004550:0.003866:0.003866:0.003866:0.004550:0.006636:0.005798:0.010399:0.011716:0.009168:0.004550:0.011203:0.005371:0.004550:0.005798:0.010434:0.011118:0.004539:0.011067:0.011682:0.005046:0.011716:0.003421:0.011203:0.011665:0.005080:0.011203:0.005798:0.011118:0.011043:0.005679
tive effect of dexrazoxane  (Cardioxane) :@0.559983:0.775954:0.919291:0.775954:0.919291:0.761948:0.559983:0.761948:0.005798:0.003421:0.009476:0.011118:0.009869:0.011118:0.005419:0.005371:0.011118:0.011067:0.005798:0.009869:0.011203:0.005371:0.009869:0.011716:0.011118:0.008210:0.005148:0.011682:0.007269:0.011203:0.008210:0.011682:0.010434:0.011118:0.004738:0.005116:0.006312:0.013906:0.011682:0.005044:0.011716:0.003421:0.011203:0.008210:0.011682:0.010434:0.011118:0.006312:0.004738
in advanced/metastatic breast cancer :@0.559983:0.790523:0.919277:0.790523:0.919277:0.776518:0.559983:0.776518:0.003421:0.010434:0.014265:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.007475:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.014265:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.014265:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
patients:@0.559983:0.805093:0.626536:0.805093:0.626536:0.791088:0.559983:0.791088:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636
treated:@0.650294:0.805093:0.712600:0.805093:0.712600:0.791088:0.650294:0.791088:0.005798:0.005075:0.011118:0.011682:0.005798:0.011118:0.011716
with:@0.736358:0.805093:0.770225:0.805093:0.770225:0.791088:0.736358:0.791088:0.014214:0.003421:0.005798:0.010434
anthracycline-:@0.793983:0.805093:0.914524:0.805093:0.914524:0.791088:0.793983:0.791088:0.011682:0.010434:0.005798:0.010434:0.005138:0.011682:0.011067:0.009168:0.011067:0.003421:0.003421:0.010434:0.011118:0.005679
based chemotherapy. :@0.559983:0.819663:0.758397:0.819663:0.758397:0.805658:0.559983:0.805658:0.011665:0.011682:0.006636:0.011118:0.011716:0.011255:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010420:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
Ann  Oncol.:@0.764893:0.819663:0.865380:0.819663:0.865380:0.805658:0.764893:0.805658:0.012657:0.010434:0.010434:0.004738:0.006498:0.014864:0.010434:0.011067:0.011203:0.003421:0.004738
  2006 :@0.865380:0.819663:0.919267:0.819663:0.919267:0.805658:0.865380:0.805658:0.004738:0.006508:0.009476:0.009476:0.009476:0.009476:0.004738
Apr;17(4):614-22. :@0.559983:0.834233:0.702514:0.834233:0.702514:0.820227:0.559983:0.820227:0.012657:0.011665:0.005148:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738:0.004738
51.  Biganzoli L, Cufer T, Bruning P, :@0.523636:0.848802:0.813324:0.848802:0.813324:0.834797:0.523636:0.834797:0.009476:0.009476:0.004738:0.012657:0.000000:0.009818:0.003421:0.011511:0.011682:0.010434:0.007269:0.011203:0.003421:0.003421:0.006739:0.007902:0.004738:0.006727:0.013906:0.010399:0.005371:0.011118:0.005148:0.006724:0.005538:0.004738:0.006727:0.009818:0.005148:0.010399:0.010434:0.003421:0.010434:0.011511:0.006727:0.008017:0.004738:0.004738
et al:@0.815317:0.848802:0.854063:0.848802:0.854063:0.834797:0.815317:0.834797:0.011118:0.005798:0.006727:0.011682:0.003421
. Doxo-:@0.854063:0.848802:0.914551:0.848802:0.914551:0.834797:0.854063:0.834797:0.004738:0.006729:0.012726:0.011203:0.008210:0.011203:0.005679
rubicin-paclitaxel: a safe regimen in terms :@0.559983:0.863372:0.919299:0.863372:0.919299:0.849367:0.559983:0.849367:0.005148:0.010399:0.011665:0.003421:0.011067:0.003421:0.010434:0.005679:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.004738:0.006568:0.011682:0.006568:0.006636:0.011682:0.005371:0.011118:0.006568:0.005078:0.011118:0.011511:0.003421:0.016044:0.011118:0.010434:0.006568:0.003421:0.010434:0.006568:0.005798:0.011118:0.005617:0.016044:0.006636:0.004738
of cardiac toxicity in metastatic breast car-:@0.559983:0.877942:0.914539:0.877942:0.914539:0.863936:0.559983:0.863936:0.011203:0.005371:0.004293:0.011067:0.011682:0.005044:0.011716:0.003421:0.011682:0.011067:0.004293:0.005798:0.011203:0.008210:0.003421:0.011067:0.003421:0.005798:0.009168:0.004293:0.003421:0.010434:0.004293:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.004293:0.011665:0.005082:0.011118:0.011682:0.006636:0.005798:0.004293:0.011067:0.011682:0.005148:0.005679
cinoma patients. Results from a European :@0.559983:0.892511:0.919274:0.892511:0.919274:0.878506:0.559983:0.878506:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.006979:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.004738:0.006979:0.010382:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.006979:0.005371:0.005077:0.011203:0.016044:0.006979:0.011682:0.006979:0.009168:0.010399:0.005080:0.011203:0.011665:0.011118:0.011682:0.010434:0.004738
Organization  for  Research and Treatment :@0.559983:0.907081:0.919305:0.907081:0.919305:0.893076:0.559983:0.893076:0.014864:0.005164:0.011511:0.011682:0.010434:0.003421:0.007269:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.002966:0.005371:0.011203:0.005148:0.004738:0.002964:0.010382:0.011118:0.006636:0.011118:0.011682:0.005030:0.011067:0.010434:0.007714:0.011682:0.010434:0.011716:0.007714:0.006773:0.005078:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
of  Cancer  multicenter  trial. :@0.559983:0.921357:0.797010:0.921357:0.797010:0.907352:0.559983:0.907352:0.011203:0.005371:0.004738:0.003394:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.003390:0.016044:0.010399:0.003421:0.005798:0.003421:0.011067:0.011118:0.010434:0.005798:0.011118:0.005148:0.004738:0.003388:0.005798:0.005148:0.003421:0.011682:0.003421:0.004738:0.004738
Cancer.:@0.800414:0.921357:0.868506:0.921357:0.868506:0.907352:0.800414:0.907352:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
 2003 :@0.868494:0.921357:0.919277:0.921357:0.919277:0.907352:0.868494:0.907352:0.008142:0.009476:0.009476:0.009476:0.009476:0.004738
Jan 1;97(1):40-5.:@0.559983:0.935633:0.693927:0.935633:0.693927:0.921627:0.559983:0.921627:0.008244:0.011682:0.010434:0.004738:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.005679:0.009476:0.004738